TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Shifting Sedentary Behaviors to Light Activities on Energy Expenditure: A Randomized Controlled Trial in Sedentary Adults
Brief Summary: The main purposes of this randomized cross-over trial are to test if a 3h/day reduction of time spent in sedentary behaviour (SB) through breaking up hourly and shifting it for standing and walking behaviours would substantially increase total (TEE) and PA energy expenditure (PAEE) compared to a week of habitual prolonged SB, in male and female overweight/obese inactive (which do not attained MVPA recommendations) and sedentary desk workers. Specifically using an experiment design our main aims are: a) to determine the impact of reducing SB on TEE and PAEE; b) to analyse the independent effects of interrupting SB through breaks and the overall reduction in SB on TEE and PAEE; c) To analyse the determinants for the overall reduction in SB; d) If the changes occurred in TEE and PAEE were dependent on specific covariates.


Options:
A: Arm Label: tailored group; Type: EXPERIMENTAL; Interventions: Behavioral: Start to stand | Arm Label: generic group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: generic advice | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Start to stand; Assigned to Arm(s): tailored group | Intervention Type: BEHAVIORAL; Name: generic advice; Assigned to Arm(s): generic group
B: Arm Label: Lifestyle change; Type: EXPERIMENTAL; Interventions: Behavioral: Reduction of sedentary time by breaking it with low intensity physical activity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Reduction of sedentary time by breaking it with low intensity physical activity; Assigned to Arm(s): Lifestyle change
C: Arm Label: Reduction in sitting time; Type: EXPERIMENTAL; Interventions: Behavioral: Sedentary behavior | Arm Label: Increase in sit-to-stand transitions; Type: EXPERIMENTAL; Interventions: Behavioral: Sedentary behavior | Intervention Type: BEHAVIORAL; Name: Sedentary behavior; Assigned to Arm(s): Increase in sit-to-stand transitions, Reduction in sitting time
D: Arm Label: Physical activity treatment group; Type: EXPERIMENTAL; Interventions: Behavioral: Pedal@Work | Arm Label: Wait List Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Pedal@Work Worksite Wellness | Intervention Type: BEHAVIORAL; Name: Pedal@Work Worksite Wellness; Assigned to Arm(s): Wait List Control | Intervention Type: BEHAVIORAL; Name: Pedal@Work; Assigned to Arm(s): Physical activity treatment group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Shifting Sedentary Behaviors to Light Activities on Energy Expenditure: A Randomized Controlled Trial in Sedentary Adults
Brief Summary: The main purposes of this randomized cross-over trial are to test if a 3h/day reduction of time spent in sedentary behaviour (SB) through breaking up hourly and shifting it for standing and walking behaviours would substantially increase total (TEE) and PA energy expenditure (PAEE) compared to a week of habitual prolonged SB, in male and female overweight/obese inactive (which do not attained MVPA recommendations) and sedentary desk workers. Specifically using an experiment design our main aims are: a) to determine the impact of reducing SB on TEE and PAEE; b) to analyse the independent effects of interrupting SB through breaks and the overall reduction in SB on TEE and PAEE; c) To analyse the determinants for the overall reduction in SB; d) If the changes occurred in TEE and PAEE were dependent on specific covariates.


Options:
A: Arm Label: Treadmill workstation; Type: EXPERIMENTAL; Interventions: Behavioral: Treadmill workstation, Behavioral: Health talk | Arm Label: Control group; Type: EXPERIMENTAL; Interventions: Behavioral: Health talk | Intervention Type: BEHAVIORAL; Name: Treadmill workstation; Assigned to Arm(s): Treadmill workstation | Intervention Type: BEHAVIORAL; Name: Health talk; Assigned to Arm(s): Control group, Treadmill workstation
B: Arm Label: High intensity intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Arm Label: Low intensity intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): High intensity intervention group, Low intensity intervention group
C: Arm Label: Lifestyle change; Type: EXPERIMENTAL; Interventions: Behavioral: Reduction of sedentary time by breaking it with low intensity physical activity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Reduction of sedentary time by breaking it with low intensity physical activity; Assigned to Arm(s): Lifestyle change
D: Arm Label: education only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: education talk and leaflet | Arm Label: prompt + education; Type: EXPERIMENTAL; Interventions: Device: MyRestBreak 1.0, Behavioral: education talk and leaflet | Intervention Type: DEVICE; Name: MyRestBreak 1.0; Assigned to Arm(s): prompt + education | Intervention Type: BEHAVIORAL; Name: education talk and leaflet; Assigned to Arm(s): education only, prompt + education

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Shifting Sedentary Behaviors to Light Activities on Energy Expenditure: A Randomized Controlled Trial in Sedentary Adults
Brief Summary: The main purposes of this randomized cross-over trial are to test if a 3h/day reduction of time spent in sedentary behaviour (SB) through breaking up hourly and shifting it for standing and walking behaviours would substantially increase total (TEE) and PA energy expenditure (PAEE) compared to a week of habitual prolonged SB, in male and female overweight/obese inactive (which do not attained MVPA recommendations) and sedentary desk workers. Specifically using an experiment design our main aims are: a) to determine the impact of reducing SB on TEE and PAEE; b) to analyse the independent effects of interrupting SB through breaks and the overall reduction in SB on TEE and PAEE; c) To analyse the determinants for the overall reduction in SB; d) If the changes occurred in TEE and PAEE were dependent on specific covariates.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: ALIVE | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ALIVE; Assigned to Arm(s): Intervention
B: Arm Label: Sit-Stand Desk; Type: EXPERIMENTAL; Interventions: Other: Sit-Stand Desk | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Sit-Stand Desk; Assigned to Arm(s): Sit-Stand Desk
C: Arm Label: Lifestyle change; Type: EXPERIMENTAL; Interventions: Behavioral: Reduction of sedentary time by breaking it with low intensity physical activity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Reduction of sedentary time by breaking it with low intensity physical activity; Assigned to Arm(s): Lifestyle change
D: Arm Label: multi-component intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Sit-stand workstation provision | Arm Label: Sit-stand workstation only; Type: EXPERIMENTAL; Interventions: Behavioral: Sit-stand workstation provision | Arm Label: Usual practice (seated workstation); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Sit-stand workstation provision; Assigned to Arm(s): Sit-stand workstation only, multi-component intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy
Brief Summary: This global, multicenter, open-label, randomized, controlled study evaluated the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 \[anti-PD-L1\] antibody)compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure with platinum-containing chemotherapy. Participants were randomized 1:1 to receive either docetaxel or atezolizumab. Treatment may continue as long as participants experienced clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.


Options:
A: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Docetaxel; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Docetaxel
B: Arm Label: Pembrolizumab 2 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Pembrolizumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Docetaxel 75 mg/m^2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab 10 mg/kg, Pembrolizumab 2 mg/kg | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Docetaxel 75 mg/m^2
C: Arm Label: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab | Arm Label: Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Docetaxel
D: Arm Label: (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Cisplatin, Drug: Gemcitabine, Drug: Pemetrexed | Arm Label: Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody; Assigned to Arm(s): Atezolizumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: EFFECT OF SHORT-TERM TREATMENT WITH THE SYNBIOTIC PROBINUL-NEUTRO® ON GASTROINTESTINAL SYMPTOMS AND CIRCULATING PLASMA p-CRESOL LEVEL IN PATIENTS WITH CHRONIC RENAL FAILURE: A RANDOMIZED DOUBLE BLIND PILOT STUDY.
Brief Summary: The interest on gastrointestinal (GI) dysfunction in CKD has been growing in the last years. it is now accepted that GI dysfunction in dialyzed patients may contribute to systemic microinflammation by promoting gut dysbiosis and bacterial translocation in the blood. Another mechanism by which GI dysfunction contributes to systemic symptoms in CKD is related to metabolic activity of the dysbiotic microflora growing in the gut of these patients to generate toxic compounds such as phenols, indoles, and amines. Epidemiological evidence has strongly linked one of these compounds, p-Cresol, to cardiovascular risk and mortality in CKD. In the present paper the investigators investigated the effect of a probiotic/prebiotic mixture on plasma p-cresol concentrations and GI symptoms and in CKD patients not on dialysis yet.


Options:
A: Arm Label: Probiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Probiotic | Arm Label: Prebiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Prebiotic | Arm Label: Symbiotic; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Symbiotic | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic; Assigned to Arm(s): Probiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotic; Assigned to Arm(s): Prebiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Symbiotic; Assigned to Arm(s): Symbiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: probiotic; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotic | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic; Assigned to Arm(s): probiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: SYNBIOTIC; Type: EXPERIMENTAL; Interventions: Dietary Supplement: SYNBIOTIC | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: SYNBIOTIC; Assigned to Arm(s): SYNBIOTIC
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cornstarch | Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Cornstarch; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Placebo-controlled, Randomized, Blinded, Dose Finding Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults
Brief Summary: The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective at reducing social anxiety in adults with autism.

The main questions it aims to answer are:

* Do two sessions of MDMA-assisted therapy reduce social anxiety?
* What dose of MDMA is most effective at reducing social anxiety?

Researchers will compare two blinded sessions of MDMA-assisted therapy to two blinded sessions of placebo with therapy.

Participants will undergo three non-drug preparatory therapy sessions before the first blinded medication session. After each medication session, participants will undergo three non-drug integrative therapy sessions.

In Stage 2, participants who received placebo with therapy in the first two blinded sessions will be able to undergo two sessions with MDMA-assisted therapy.


Options:
A: Arm Label: Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of Aripiprazole | Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Placebo of Aripiprazole; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole
C: Arm Label: Inactive Placebo with Therapy; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Therapy | Arm Label: Group 1: MDMA-assisted therapy 75 mg/100mg; Type: EXPERIMENTAL; Interventions: Drug: Midomafetamine HCl, Behavioral: Therapy | Arm Label: Group 2: MDMA-assisted therapy 100 mg/125 mg; Type: EXPERIMENTAL; Interventions: Drug: Midomafetamine HCl, Behavioral: Therapy | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Inactive Placebo with Therapy | Intervention Type: DRUG; Name: Midomafetamine HCl; Assigned to Arm(s): Group 1: MDMA-assisted therapy 75 mg/100mg, Group 2: MDMA-assisted therapy 100 mg/125 mg | Intervention Type: BEHAVIORAL; Name: Therapy; Assigned to Arm(s): Group 1: MDMA-assisted therapy 75 mg/100mg, Group 2: MDMA-assisted therapy 100 mg/125 mg, Inactive Placebo with Therapy
D: Arm Label: N-Acetyl Cysteine; Type: ACTIVE_COMPARATOR; Interventions: Drug: N-Acetyl Cysteine | Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo - sugar pill | Intervention Type: DRUG; Name: N-Acetyl Cysteine; Assigned to Arm(s): N-Acetyl Cysteine | Intervention Type: OTHER; Name: Placebo - sugar pill; Assigned to Arm(s): Sugar pill

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Study of the Effect of Senna Alexandrina Mill. on Uremic Pruritus and Serum IL-2, INF-δ and TNF-α Levels of Hemodialysed Patients
Brief Summary: Uremic pruritus remains one of the most frustrating and potentially disabling symptoms in patients with end stage renal disease. It affect up to 90 percent of patients with end stage renal disease. Several hypotheses have been postulated for the possible underlying etiology, but none is conclusive. Aside from kidney transplantation, which is only definitive treatment, therapeutic approaches have largely been empirical, and no firm evident-base treatments are available. The main goal of therapy remains to minimize severity of pruritus. In Iranian traditional medicine Cassia senna L. is used for healing uremic pruritus . In this study investigators considered to evaluate effect of Cassia senna L. in uremic pruritus by a double blind placebo control clinical trial. It is hypothesized that oral Cassia senna L. may attenuate uremic pruritus by decreasing serum IL-2, IFN-γ and TNF-α.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Wheat; Type: PLACEBO_COMPARATOR; Interventions: Drug: Wheat | Arm Label: Fumaria; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fumaria | Intervention Type: DRUG; Name: Wheat; Assigned to Arm(s): Wheat | Intervention Type: DRUG; Name: Fumaria; Assigned to Arm(s): Fumaria
C: Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Senna; Type: ACTIVE_COMPARATOR; Interventions: Drug: Senna | Intervention Type: DRUG; Name: Senna; Assigned to Arm(s): Senna | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Prospective, Observational, 4-week Inception Cohort Study Being Carried Out by the Acute Respiratory Failure Section of ESICM
Brief Summary: We wish to prospectively assess the burden of, management and therapeutic approaches to, and outcomes from acute hypoxaemic respiratory failure requiring ventilatory support, during the winter months in both the northern and southern hemispheres. We wish to specifically examine the contribution of ARDS as defined by the Berlin Definition to the burden of hypoxaemic respiratory failure.

Why?

The purpose of this study is to provide new and current data on the disease burden of acute hypoxemic respiratory failure and ARDS. It will answer the following questions:

* What is the frequency and disease burden of acute hypoxaemic respiratory failure in winter?
* What are the aetiologies of acute hypoxaemic respiratory failure requiring ventilatory support?
* What is the incidence of ARDS based on the Berlin definition within this patient cohort?
* What is the mortality from ARDS within this cohort, and how does this vary based on ARDS severity?
* What is the natural history of ARDS?
* What are the key patterns of therapeutic resource utilization, particularly approaches to sustain gas exchange, in these patients?

When?

The study is performed over a 4 week period between February 1st and March 31st 2014 in the Northern Hemisphere and June 1st to August 31st in the Southern Hemisphere.

What data is required?

A basic dataset is collected on all patients admitted with acute acute hypoxaemic respiratory failure requiring ventilatory support, with a more detailed dataset collected on patients diagnosed with ARDS.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Remdesivir; Type: EXPERIMENTAL; Interventions: Drug: Remdesivir | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Remdesivir; Assigned to Arm(s): Remdesivir
B: Arm Label: One Group; Type: N/A; Interventions: N/A
C: Arm Label: Hydroxychloroquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Remdesivir, Other: (Standard of Care) SoC | Arm Label: Remdesivir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxychloroquine, Other: (Standard of Care) SoC | Arm Label: Control group - SoC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxychloroquine, Drug: Remdesivir | Intervention Type: DRUG; Name: Hydroxychloroquine; Assigned to Arm(s): Control group - SoC, Remdesivir | Intervention Type: DRUG; Name: Remdesivir; Assigned to Arm(s): Control group - SoC, Hydroxychloroquine | Intervention Type: OTHER; Name: (Standard of Care) SoC; Assigned to Arm(s): Hydroxychloroquine, Remdesivir
D: Arm Label: Remdesivir group; Type: EXPERIMENTAL; Interventions: Drug: Remdesivir | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Remdesivir placebo | Intervention Type: DRUG; Name: Remdesivir; Assigned to Arm(s): Remdesivir group | Intervention Type: DRUG; Name: Remdesivir placebo; Assigned to Arm(s): Control group

Answer: B